Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

A new case before the Supreme Court targeting preventive coverage mandates under Obamacare gives President-elect Donald Trump a chance to undermine one of the most controversial aspects of the healthc ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

The federal government said Gilead failed to compensate the CDC for discovering that Truvada can prevent HIV ... drug's HIV-prevention regimen, known as PrEP, or pre-exposure prophylaxis, ignored ...

Meal prep can look different from person to person: For some, it’s chopping a bunch of ingredients up (a.k.a. mise en place) and storing them until you’re ready to assemble your dish ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

Each Prep student attending a Victorian government school will receive a Prep bag to celebrate this milestone in their education journey. Each Prep student attending a Victorian government school in ...